Personalized medicine of oral molecular-targeted anticancer drugs for elderly patients
Project/Area Number |
17K08408
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Medical pharmacy
|
Research Institution | Akita University |
Principal Investigator |
Miura Masatomo 秋田大学, 医学部附属病院, 教授 (30265194)
|
Project Period (FY) |
2017-04-01 – 2020-03-31
|
Project Status |
Completed (Fiscal Year 2019)
|
Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
Keywords | 分子標的抗がん剤 / 血中濃度 / 遺伝子多型 / 高齢者 / レンバチニブ / ボスチニブ / 投与量 |
Outline of Final Research Achievements |
Plasma concentrations of molecular-targeted anticancer drugs in the elderly patients were higher than those in younger patients. For the elderly patients, the dose escalation regimen of molecular-targeted anticancer drugs was better than the standard dose regimen at avoiding treatment interruption due to side effects. The daily dose of molecular-targeted anticancer drugs might be adjusted based on target plasma concentration to avoid adverse events by therapeutic drug monitoring.
|
Academic Significance and Societal Importance of the Research Achievements |
高齢患者への薬の投与は、成人という大きな括りの中で、添付文書記載の標準投与量で治療が行われている。しかし高齢患者において標準投与量は高用量になることが多く、特に分子標的抗がん剤の場合、投与開始2週間以内に重篤な副作用が出現し、治療中断に至るケースが散見される。今後、日本人の3人に1人が65歳以上になる高齢化社会を迎えるに当たって、高齢がん患者に適した治療法を再考する必要がある。本研究成果は、高齢者には低用量から投与を開始し、各分子標的抗がん剤の固有のターゲット血中濃度を指標に、投与量を段階的に増量することが必要であることを示している。
|
Report
(4 results)
Research Products
(24 results)
-
-
-
-
-
-
-
-
-
[Journal Article] Contribution of UGT1A1 genetic polymorphisms related to axitinib pharmacokinetics to safety and efficacy in patients with renal cell carcinoma.2018
Author(s)
Igarashi R, Inoue T, Fujiyama N, Tsuchiya N, Numakura K, Kagaya H, Saito M, Narita S, Satoh S, Niioka T, Miura M, Habuchi T.
-
Journal Title
Med Oncol.
Volume: 35(51)
Issue: 4
Pages: 51-58
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
-
-
-
-
[Presentation] fficacy and Safety of Tyrosine Kinase Inhibitors for Treatment of Newly Diagnosed Chronic Myeloid Leukemia: Results Using Data Obtained with the New Target System from the Japanese Registry.2018
Author(s)
Takahashi, N., Kizaki, M., Miura, M., Kawaguchi, T., Suzuki, R., Yamamoto, K., Ohnishi, K., Matsumura, I., Naoe, T., Akashi, K.
Organizer
60th American Society of Hematology Annual Meeting and Exposition
Related Report
Int'l Joint Research
-
[Presentation] Pharmacokinetic and Pharmacogenetic Analysis of Bosutinib in Japanese Patients with Chronic-Phase Chronic Myeloid Leukemia2018
Author(s)
Mita, A., Abumiya, M., Takahashi, S., Kameoka, Y., Miura, M., Takahashi, N
Organizer
60th American Society of Hematology Annual Meeting and Exposition
Related Report
Int'l Joint Research
-
-
[Presentation] Effects of polymorphisms of NR1I2, CYP3A4 and ABC transporters on the concentrations of bosutinib2018
Author(s)
Abumiya, M., Mita, A., Yoshioka, T., Kameoka, Y., Takahashi, N., Miura, M.
Organizer
第80回日本血液学会学術集会
Related Report
-
-
-
-
-